C4Diagnostics, the infectious diseases diagnostics start-up, receives three awards in less than 3 weeks

- **October 27th, 2017**: Winner of the Invest Award of INNOV’inMED 2017
- **October 17th, 2017**: First company to integrate into Ze Lab, the biotech & pharma accelerator of the Cisbio group.
- **October 9th, 2017**: Finalist (top 3) International Prize Universal Biotech Innovation Award 2017 (262 candidates, 31 countries represented, the only French company to reach the final)

Marseille, November 3rd. This autumn is rich in awards for biotech start-up company C4Diagnostics, which is currently developing a breakthrough technology for in vitro diagnosis of infectious diseases based on patents from the CNRS and the University of Aix-Marseille.

After its first international recognition in the Universal Biotech Innovation 2017 competition and its integration into the accelerator Cisbio group, a leading player in in vitro diagnostics and life sciences, today C4Diagnostics announces that it has won the Invest Award of INNOV’inMed 2017, awarded by a jury of investment funds and innovation professionals.

These numerous announcements come as the company is in the process of raising funds and is in discussions with various associations of business angels as well as French and international investment funds.

“This latest award is very exciting for us, and is a recognition of the work of the team and of our partners and advisors, who have accompanied us through the different stages from the beginning of the company. It is extremely encouraging for the next steps in our development” says Younes Lazrak, President of C4Diagnostics.

About C4Diagnostics

C4Diagnostics is a young company from Marseille specializing in the detection and identification of pathogens. C4Diagnostics relies on a breakthrough technology, winner of the “La Recherche” prize in 2015, to identify and make visible (by staining or fluorescence) pathogenic microorganisms. As a first application of this method, C4Diagnostics provides a rapid and efficient diagnostic solution for Legionnaires’ disease, a fatal lung disease in 10% of cases and with increasing incidence. The company is also targeting the market for urinary tract infections (the incidence of which remains very high and for which C4Diagnostics will help to speed up the diagnosis), and that of antimicrobial susceptibility testing (an important public health issue considering the worrying increase in multidrug resistance more and more often observed).

www.c4diagnostics.com
Press relations: Younes Lazrak, +33 771 793 280, younes.lazrak@c4diagnostics.com